It’s been more than two years since the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China, in December 2019, and still Coronavirus-19 (COVID-19) is an ongoing burden in many parts of the world. Currently, few vaccines are approved by the World Health Organization (WHO) and are being administered to people to boost their immunity. Since the outbreak of this disease, the number of patients getting vaccinated is increasing with every passing day. Understanding the burden of the disease and the adverse effects due to its vaccination is very crucial. We report a case of Guillain-Barre Syndrome after receiving the first dose of the AstraZeneca-COVID-19 vaccine.
Cite this paper
Hassan, A. M. , Marium, S. , Yousuf, P. , Farooqi, A. A. and Yaqoob, U. (2022). Guillain-Barré Syndrome Following AstraZeneca COVID-19 Vaccine. Open Access Library Journal, 9, e9510. doi: http://dx.doi.org/10.4236/oalib.1109510.
Guan, W.J., Ni, Z.Y., Hu, Y., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 30, 1708-1720.
World Health Organization (2020) World Health Organization Coronavirus Disease (COVID-19) Dashboard. World Health Organization, Geneva.
http://www.who.int/emergencies/diseases/novel-coronavirus-2019?adgroupsurvey={adgroupsurvey}&gclid=Cj0KCQjwjIKYBhC6AR....
Leclerc, S., Royal, V., Lamarche, C. and Laurin, L.P. (2021) Minimal Change Disease with Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report. American Journal of Kidney Diseases, 78, 607-610.
https://doi.org/10.1053/j.ajkd.2021.06.008
Waheed, S., Bayas, A., Hindi, F., Rizvi, Z. and Espinosa, P.S. (2021) Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus, 13, e13426.
Nasuelli, N.A., De Marchi, F., Cecchin, M., et al. (2021) A Case of Acute Demyelinating Polyradiculoneuropathy with Bilateral Facial Palsy after ChAdOx1 nCoV-19 Vaccine. Neurological Sciences, 42, 4747-4749.
https://doi.org/10.1007/s10072-021-05467-w
James, J., Jose, J., Gafoor, V.A., Smita, B. and Balaram, N. (2021) Guillain-Barré Syndrome Following ChAdOx1 nCoV-19 COVID-19 Vaccination: A Case Series. Neurology and Clinical Neuroscience, 9, 402-405.
https://doi.org/10.1111/ncn3.12537
Introna, A., Caputo, F., Santoro, C., Guerra, T., Ucci, M., Mezzapesa, D.M. and Trojano, M. (2021) Guillain-Barré Syndrome after AstraZeneca COVID-19-Vaccination: A Causal or Casual Association? Clinical Neurology and Neurosurgery, 208, 106887.
https://doi.org/10.1016/j.clineuro.2021.106887
Toscano, G., Palmerini, F., Ravaglia, S., et al. (2020) Guillain-Barré Syndrome Associated with SARS-CoV-2. New England Journal of Medicine, 382, 2574-2576.
https://doi.org/10.1056/NEJMc2009191
Jacobs, B.C., Rothbarth, P.H., Van der Meché, F.G., Herbrink, P., Schmitz, P.I., De Klerk, M.A. and Van Doorn, P.A. (1998) The Spectrum of Antecedent Infections in Guillain-Barré Syndrome: A Case-Control Study. Neurology, 51, 1110-1115.
https://doi.org/10.1212/WNL.51.4.1110
Ramasamy, M.N., Minassian, A.M., Ewer, K.J., et al. (2020) Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial. Lancet, 396, 1979-1993. https://doi.org/10.1016/S0140-6736(20)32466-1
